

Diagnosis and complications of retinal vascular disease developing in preterm children

Submission date 15/07/2018	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 24/07/2018	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 06/11/2019	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Babies born prematurely have a very low birth weight. In Turkey, 25,000 very low weight babies are born annually, with around 1000 of them facing the risk of blindness (retinopathy of prematurity (ROP)).

The likelihood of these babies developing ROP is affected by the treatment and follow-up that they receive, along with any complications. We retrospectively reviewed the treatment, follow-up period and treatment complications of 302 premature, low birth weight babies who were examined for ROP at SBÜ Bursa YİEAH ROP between the dates of February 2016 to February 2017, to determine the effects of treatment and complications of ROP and demonstrate that complete rehabilitation can be achieved with strict follow-up and appropriate treatment.

Who can participate?

Premature babies, born between 6 and 35 weeks of gestation

What does the study involve?

There is no direct participation for infants involved in the study. Instead, this is a retrospective review of the treatment, follow-up period and treatment complications of participants.

What are the possible benefits and risks of taking part?

The possible benefit of taking part is that it may help prevent severe vision loss in future premature babies. There are no known risks to participants taking part in this study.

Where is the study run from?

SBU Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

When is the study starting and how long is it expected to run for?

1st July 2018 to 15th July 2018

Who is funding the study?

1. Social Security Institution (Turkey)
2. SBU Bursa Yüksek İhtisas Training and Research Hospital (Turkey)

Who is the main contact?

1. Müberra Akdoğan (mbrakdogan@yahoo.com)
2. Görkem Çevik (gorkemcevic@hotmail.com)

Contact information

Type(s)

Scientific

Contact name

Mrs Müberra Akdoğan

ORCID ID

<https://orcid.org/0000-0003-4846-312X>

Contact details

Mursel Mah. Eğitim Cad. 16. sok. Sevilla Villaları G1 villa no.1
Bursa
Türkiye
16110
05052408229
mbrakdogan@yahoo.com

Type(s)

Scientific

Contact name

Dr Sadık Görkem Çevik

ORCID ID

<https://orcid.org/0000-0002-5653-5800>

Contact details

SBU Bursa Yüksek İhtisas Training and Research Hospital
Mimar Sinan Mah. Emniyet Cad. Polis Okulu Karşısı Yıldırım
Bursa
Türkiye
16310
+90 224 295 50 00
gorkemcevic@hotmail.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

7929783.v1

Study information

Scientific Title

Diagnosis, treatment and complications of retinopathy of prematurity

Acronym

ROP

Study objectives

To determine the effects of diagnosis, treatment and complications of retinopathy of prematurity and demonstrate that complete rehabilitation can be achieved with strict follow-up and appropriate treatment of severe ROP

Ethics approval required

Old ethics approval format

Ethics approval(s)

SBU Bursa Higher Specialized Education Research Hospital, 01/07/2018, 31234050-514.10

Study design

Observational cross sectional retrospective review

Primary study design

Observational

Study type(s)

Screening

Health condition(s) or problem(s) studied

Retinopathy of prematurity

Interventions

Records were reviewed, using the International Classification of Retinopathy of Prematurity (ICROP) criteria to review diagnoses and the Early Treatment of Retinopathy of Prematurity (ETROP) study group criteria to review treatments.

Intervention Type

Mixed

Primary outcome(s)

The following were measured from birth to the end of the follow-up period:

1. Total maturation of retinal vascularisation
2. IVB (intravitreal bevacizumab) dose
3. LPC (laser photocoagulation) treatment
4. Complications after treatment
5. Stage of ROP
6. Gender of infant
7. Follow-up duration (weeks)
8. Gestational week of birth
9. Incubation duration (days)

Key secondary outcome(s)

N/A

Completion date

15/07/2018

Eligibility**Key inclusion criteria**

Preterm babies born between 6 and 35 weeks of gestation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Sex

All

Key exclusion criteria

N/A

Date of first enrolment

01/02/2016

Date of final enrolment

01/02/2017

Locations**Countries of recruitment**

Türkiye

Study participating centre

Department of Ophthalmology, University of Health Sciences (SBU) Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

SBÜ Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Mimarsinan Mahallesi, No:, Emniyet Cd. No:35, 16310 Yıldırım/Bursa

BURSA

Türkiye

16310

Sponsor information

Organisation

Department of Ophthalmology, University of Health Sciences (SBU) Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Turkey

ROR

<https://ror.org/05nhkt138>

Funder(s)

Funder type

Not defined

Funder Name

Absent

Results and Publications

Individual participant data (IPD) sharing plan

Retinal images (if available) and clinical follow-up information without the patient's identity information can be obtained from mbrakdogan@yahoo.com.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	08/03/2015		Yes	No
Participant information sheet			02/04/2019	No	Yes